<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180801</url>
  </required_header>
  <id_info>
    <org_study_id>FLU-v-004</org_study_id>
    <secondary_id>2016-002134-74</secondary_id>
    <secondary_id>2015-25472</secondary_id>
    <nct_id>NCT03180801</nct_id>
  </id_info>
  <brief_title>Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model</brief_title>
  <official_title>Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepTcell Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>PepTcell Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FLU-v is a broad spectrum influenza vaccine that targets regions conserved among multiple
      influenza strains. FLU-v adjuvanted with Montanide ISA-51 was shown to be safe in previous
      trials. This study aims to assess efficacy of adjuvanted FLU-v vaccine in protecting healthy
      volunteers against an influenza challenge delivered intranasally under quarantine.

      Efficacy of FLU-v will be assessed by measuring the incidence and severity of the disease in
      the treatment groups compared to the placebo group. In addition, the immune responses of the
      volunteers to FLU-v will also be explored.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Influenza is a highly variable virus. Most of the variability comes from the proteins on the
      viral capsid surface; NA and HA. Current vaccines use these highly variable, immunogenic
      proteins to induce production of neutralising antibodies, however because these proteins are
      different for each strain, and can also change over time within strains due to antigenic
      drift, a new vaccine is required each year designed specifically to the strain predicted to
      circulate that year. In the event of a mismatch between predicted and actual circulating
      strains, or the emergence of a new strain due to antigenic shift, the effectiveness of the
      annual vaccine is drastically reduced. These limitations are further compounded by the short
      manufacturing window between strain prediction and the start of the influenza season, as well
      as the limited supply of suitable eggs used for vaccine production. As a result of these
      issues, only a limited supply of annual vaccine is available.

      FLU-v, a novel peptide vaccine, aims to provide a broad-spectrum response using peptide
      antigens matching immunogenic regions of conserved viral proteins found inside the viral
      capsid. These antigens have been shown to induce cytotoxic T-cell responses and
      non-neutralising antibodies in both pre-clinical and clinical studies. The FLU-v vaccine
      administered with and without adjuvant has been demonstrated to be safe in previous trials,
      and addition of adjuvant Montanide ISA-51 was shown to produce superior immunological
      responses compared to non-adjuvanted FLU-v. Data from a previous phase IIb study conducted as
      part of the UNISEC consortium suggest that the cellular and/or humoral responses resulting
      from vaccination with adjuvanted FLU-v may reduce influenza symptom severity and duration,
      although the study was not powered to assess these efficacy measures.

      Presently, efficacy will be evaluated as a primary endpoint alongside safety as part of a
      single centre, placebo controlled, phase IIb viral challenge study, using influenza A 2009
      H1N1 human virus, in suitable healthy subjects aged 18-60 years. Two dosing regimens will be
      explored. In addition, immunological endpoints will be addressed as exploratory endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2016</start_date>
  <completion_date type="Actual">May 25, 2017</completion_date>
  <primary_completion_date type="Actual">March 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Mild to Moderate Influenza Disease (MMID)</measure>
    <time_frame>From 24h post-viral inoculation (Day 1) until the end of the quarantine phase on Day 7</time_frame>
    <description>To determine the effect of FLU-v on reducing the incidence of Mild to Moderate Influenza Disease (MMID) defined as detectable viral shedding by Luminex Respiratory Pathogen Panel Test (RPP) in the presence of at least one influenza symptom.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAEs) Per Subject.</measure>
    <time_frame>From the first vaccination on day -43 to the last follow up visit on day 63.</time_frame>
    <description>To determine the number of TEAEs that were reported after the first administration of the vaccine until the end of the study (overall) and then separated into pre-inoculation (events reported from the time of first vaccination up to Day 0 prior to time of inoculation) and post-inoculation (Day 0 inoculation time through study completion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Treatment Emergent Adverse Event Classified by Relatedness and Severity.</measure>
    <time_frame>From the day of the first vaccination up to the end of the study on day +63.</time_frame>
    <description>Number of subjects with one or more AE are reported by severity (mild, moderate and severe) and relatedness to vaccine or challenge virus inoculation (definitely, probably, possibly, unlikely, not related).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Detectable Viral Shedding and Number of Subjects With Recorded Influenza Symptoms During the Quarantine Period.</measure>
    <time_frame>Quarantine period from day 1 to day 7 post-inoculation.</time_frame>
    <description>Number of subjects experiencing at least one influenza symptom and at least two influenza symptoms.
Number of subjects with detectable shedding by RPP (Luminex) test from nasal swabs.
Number asymptomatic subjects with detectable virus by RPP (Luminex) test from nasal swabs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Shedding Duration</measure>
    <time_frame>starting from evening of Day 1 post-inoculation up to Day 7.</time_frame>
    <description>Number of days with detectable viral shedding measured using the Luminex Respiratory Pathogen Panel test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Viral Shedding (Area Under the Curve)</measure>
    <time_frame>from the evening of Day 1 post-inoculation to the morning of Day 7 (last timepoint before expected quarantine discharge)</time_frame>
    <description>Shedding is quantified by RT-PCR from nasal swabs taken twice daily (am/pm) during the quarantine period. Plotting the log copy number/ml for each time point against time is done to calculate the area under the curve (AUC) using the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Viral Load</measure>
    <time_frame>from the evening of Day 1 post-inoculation to the morning of Day 7 (last timepoint before expected quarantine discharge)</time_frame>
    <description>Shedding is quantified by RT-PCR from nasal swabs taken twice daily (am/pm) during the quarantine period. Peak viral load is the highest recorded log10copy number/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Influenza Symptoms</measure>
    <time_frame>from the evening of Day 1 post-inoculation to the morning of Day 7 (last timepoint before expected quarantine discharge)</time_frame>
    <description>Subjects were assessed by the physician whilst under quarantine post-inoculation. The number of days subjects experienced influenza symptoms was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptoms Experienced Per Subject Per Day.</measure>
    <time_frame>from the evening of Day 1 post-inoculation to the morning until the day of last symptom noted during the expected quarantine period (up tp Day 7)</time_frame>
    <description>Mean of total number of symptoms (upper and lower respiratory and systemic symptoms) experienced calculated as the total sum of symptoms experienced divided by the number of days in which symptoms were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Number of Symptoms Experienced Per Subject in a Single Day.</measure>
    <time_frame>from the evening of Day 1 post-inoculation until the day of last symptom noted during the expected quarantine period (up to Day 7).</time_frame>
    <description>The highest level of the total sum of all upper and lower respiratory tract and systemic symptoms recorded on any day starting from the evening of Day 1 post-inoculation until the day of last symptom noted during the expected quarantine period (up to Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Self-reported Influenza Symptoms by FLU-PRO Questionnaire.</measure>
    <time_frame>from Day 1 post-inoculation until the day 7.</time_frame>
    <description>FLU-PRO assesses 32 influenza symptoms. Subjects rate each symptom on a 5-point ordinal scale, with higher scores indicating a more frequent sign or symptom. For 27 of the items, the scale is as follows: 0 (&quot;Not at all&quot;), 1 (&quot;A little bit&quot;), 2 (&quot;Somewhat&quot;), 3 (&quot;Quite a bit&quot;), and 4 (&quot;Very much&quot;). For 5 items, severity is assessed in terms of numerical frequency, i.e., vomiting or diarrhea (0 times, 1 time, 2 times, 3 times, or 4 or more times); with frequency of sneezing, coughing, and coughed up mucus or phlegm evaluated on a scale from 0 (&quot;Never&quot;) to 4 (&quot;Always&quot;).The FLU-PRO total score is computed as a mean score across all 32 items comprising the instrument. Total scores can range from 0 (symptom free) to 4 (very severe symptoms).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogenicity of FLU-v</measure>
    <time_frame>At Screening (Day -90 to Day -43), Post-vaccination (Day -2/Day -1/Day 0) and post-influenza challenge (Day 35/Day 63)</time_frame>
    <description>To determine the antibody and cellular responses specific to FLU-v.</description>
  </other_outcome>
  <other_outcome>
    <measure>Broadness of Protection</measure>
    <time_frame>At Screening (Day -90 to Day -43), Post-vaccination (Day -2/Day -1/Day 0) and post-influenza challenge (Day 35/Day 63)</time_frame>
    <description>To determine whether the cellular responses induced by vaccination with FLU-v are able to recognize antigenically different strains of influenza (ie. H1N1, H3N2, H5N1) and in doing so demonstrating the broadness of the response. For this PBMCs from prevaccination, post-vaccination and post-challenge from subjects will be exposed in vitro to different influenza virus strains. Viral recognition by PBMCs will be assessed by measuring secretion of inflammatory cytokines and other inflammatory mediators using techniques such as multiplex ELISA.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1 adjuvanted placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 adjuvanted FLU-v one dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 adjuvanted FLU-v two doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adjuvanted FLU-v</intervention_name>
    <description>Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51</description>
    <arm_group_label>Group 2 adjuvanted FLU-v one dose</arm_group_label>
    <arm_group_label>Group 3 adjuvanted FLU-v two doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adjuvanted placebo</intervention_name>
    <description>Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51</description>
    <arm_group_label>Group 1 adjuvanted placebo</arm_group_label>
    <arm_group_label>Group 2 adjuvanted FLU-v one dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Influenza challenge</intervention_name>
    <description>On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.</description>
    <arm_group_label>Group 1 adjuvanted placebo</arm_group_label>
    <arm_group_label>Group 2 adjuvanted FLU-v one dose</arm_group_label>
    <arm_group_label>Group 3 adjuvanted FLU-v two doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females aged ≥18 and ≤55 years of age at the point of enrolment.

          2. Willingness to remain in isolation for the duration of viral shedding and to comply
             with all study requirements.

          3. The following criteria are applicable to subjects in a heterosexual relationship and
             female subjects in a same sex relationship (i.e., the criteria do not apply to male
             subjects in a same sex relationship):

               1. True abstinence- when this is in line with the preferred and usual lifestyle of
                  the subject. (Periodic abstinence [e.g. calendar, ovulation, symptothermal,
                  post-ovulation methods] and withdrawal are not acceptable methods of
                  contraception).

                  Or

               2. Two forms of effective contraceptive methods among (between) the couple, which
                  are defined as:

                    -  For males: condom with spermicidal foam/gel/film/cream, sterilisation (with
                       the appropriate post-vasectomy documentation of the absence of sperm in the
                       ejaculate. This applies only to males participating in the study).

                    -  For females:

             Women no longer of child bearing potential (post-menopausal females are defined as
             having a history of amenorrhea for at least 2 years, otherwise they should have
             documented status as being surgically sterile or post hysterectomy. The latter applies
             only to females participating in the study). If of childbearing potential, then
             acceptable forms of contraception include:

               -  Established (a minimum of 2 weeks prior to admission) use of oral, injected or
                  implanted hormonal methods of contraception.

               -  Placement of an intrauterine device (IUD) or intrauterine system (IUS).

               -  Barrier methods of contraception or occlusive cap (diaphragm or cervical/vault
                  caps), both with one of the following - spermicidal
                  foam/gel/film/cream/suppository.

                    -  The longevity of contraception is as follows:

             Males:

               -  Comply with agreed contraception at entry to quarantine, and continuing until 90
                  days after the date of viral challenge/last dosing with IMP (whichever occurs
                  last).

               -  Must not donate sperm following discharge from quarantine until 90 days after the
                  date of viral challenge/last dosing with IMP (whichever occurs last).

             Females:

             If of childbearing potential must have a negative pregnancy test at screening and just
             prior to the date of Viral Challenge, and must be using contraception consisting of
             two forms of birth control (one of which must be a barrier method) starting from at
             least 2 weeks prior to the first vaccination and continuing until 90 days after the
             date of Viral Challenge/last dosing with IMP (whichever occurs last).

          4. Willing to have samples stored for future research.

          5. Sero-suitable to the study challenge virus within 90 days of Day 0.

          6. Agrees to abstain from alcohol intake 24 hours before admission on Day -2 or Day -1
             and all other outpatient visits.

          7. Agrees to not use prescription or over-the-counter medications (including aspirin,
             decongestants, antihistamines, and other NSAIDs), and herbal medication (including,
             but not limited to, Vitamin C, Vitamin D, immune booster products, herbal tea, St.
             John's Wort), within 14 days prior to study vaccine administration through the final
             follow-up visit, unless approved by the investigator and sponsor medical monitor.

          8. An informed consent document signed and dated by the subject and the Investigator or
             delegate.

          9. A history of childhood asthma before the age of 12 years is acceptable provided the
             subject is asymptomatic without treatment. Subjects with a single episode of wheezing
             (lasting less than 2 weeks) after the age of 12 years can be included at the
             Investigator's discretion provided the episode was more than 1 year ago and did not
             require a hospital admission and/or oral/intravenous steroids.

         10. In good health with no history of major medical conditions that will interfere with
             subject safety, as defined by medical history, physical examination, and routine
             laboratory tests and determined by the Investigator at a screening evaluation.

               -  A subject with a history of Herpes type 1 or 2 infection may be included if there
                  are no active lesions present and the subject is not taking active medication.

               -  A subject with or without any evidence of atopy including any history of allergic
                  rhinitis, dermatitis, and conjunctivitis will be included as long as they do not
                  conflict with exclusion criteria. Mild to moderate arthritis of non-inflammatory
                  origin may be allowed if the subject is not at risk from relative immobility in
                  the Quarantine Unit and does not require regular medication.

         11. A documented medical history for a minimum of the last 2 years prior to inoculation.

        Exclusion Criteria:

          1. Any subjects who have smoked 10 pack years at any time. Of those subjects that have
             smoked less than 10 pack years at any time, a subject will be excluded: If regular
             smokers (e.g., smoking every day) at the time of enrolment. If current casual smoker
             or use of smoking / nicotine-related products, they must agree to refrain from smoking
             during the in-patient stay

          2. Presence of self-reported or medically documented significant medical condition
             including but not limited to:

               -  Chronic pulmonary disease (e.g., asthma (except what is stated in inclusion
                  criteria 9), COPD)

               -  Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart failure,
                  cardiac surgery, ischemic heart disease, known anatomic defects).

               -  Chronic medical conditions requiring close medical follow-up or hospitalisation
                  during the past 5 years (e.g., insulin dependent diabetes mellitus, renal
                  dysfunction, haemoglobinopathies).

               -  Immunosuppression, or immunodeficiency or ongoing malignancy.

               -  Neurological and neurodevelopmental conditions (e.g., cerebral palsy, epilepsy,
                  stroke, seizures).

               -  Post infectious or post vaccine neurological sequelae.

               -  Hyperlipidemia requiring medical therapy per current American College of
                  Cardiology (ACC) and American Heart Association (AHA) guidelines published in
                  2013.

          3. Individual with body mass index (BMI) &lt;18 and &gt;35.

          4. Acute illness within 7 days of first vaccine administration day

          5. Clinically significant abnormal electrocardiogram (ECG) and/or parameters, as
             determined by the Investigator

          6. Subjects with clinically significant abnormal systolic and diastolic blood pressure or
             clinically significant abnormal pulse rate.

          7. Subject has abnormal pulmonary function as measured by spirometry defined as a forced
             vital capacity or forced expiratory volume in 1 second (FEV1) &lt; 80% of predicted or
             peripheral arterial oxygen saturation (SpO2) &lt; 92% on room air.

          8. Known allergy to treatments for influenza (including but not limited to oseltamivir,
             nonsteroidals).

          9. Known allergy to 2 or more classes of antibiotics (e.g. penicillins, cephalosporins,
             fluoroquinolones, or glycopeptides). Known allergy to excipients in the challenge
             virus inoculum

         10. Daily or household contact with vulnerable populations.

         11. Receipt of any investigational drug:

               -  within 3 months prior to the planned date of Viral Challenge/first dosing with
                  IMP (whichever occurs first).

               -  Receipt of three or more investigational drugs within the previous 12 months
                  prior to the planned date of Viral Challenge/first dosing with IMP (whichever
                  occurs first).

               -  Prior inoculation with a virus from the same virus-family as the Challenge Virus.

               -  Prior participation in another Human Viral Challenge study with a respiratory
                  virus in the preceding 12 months taken from the date of Viral Challenge/first
                  dosing with IMP (whichever occurs first) in the previous study to the date of
                  expected Viral Challenge in this study.

         12. Receipt of any vaccine within 6 months of enrolment.

         13. Self-reported or known history of alcoholism or drug abuse (including marijuana)
             within 6 months prior to enrolment, or positive urine/serum test for drugs of abuse
             during the study

         14. Self-reported or known history of psychiatric or psychological issues that require
             treatment and are deemed by the PI to be a contraindication to protocol participation.

         15. History of a previous severe allergic reaction with generalized urticaria, angioedema,
             or anaphylaxis.

         16. History or evidence of autoimmune disease or known immunodeficiency of any cause -
             with the exception of atopic dermatitis/eczema and atopic rhinitis.

         17. Subjects with any history of physician diagnosed and/or objective test confirmed
             asthma (except as per inclusion criteria 9), reactive airway disease, COPD, pulmonary
             hypertension, or chronic lung condition of any aetiology.

         18. Positive human immunodeficiency virus (HIV) within 60 days of first vaccination visit,
             active hepatitis A (HAV), B (HBV), or C (HCV) test.

         19. Any significant abnormality altering the anatomy of the nose or nasopharynx (including
             significant nasal polyps).

         20. Venous access deemed inadequate for the phlebotomy and cannulation demands of the
             study.

         21. Any nasal or sinus surgery within 6 months of Viral Challenge.

         22. Recurrent history of fainting.

         23. Those employed or immediate relatives of those employed at hVIVO or the Sponsor.

         24. Any clinically significant history of epistaxis (nosebleeds) within the last 12 months
             and/or history of being hospitalized due to epistaxis on any previous occasion.

         25. Females who:

               -  Are breastfeeding,

               -  or have been pregnant within 6 months prior to the study,

               -  or have a positive pregnancy test at any point during screening or prior to first
                  dosing with IMP.

         26. Presence of fever, defined as subject presenting with a temperature reading of &gt;
             38.0°C on Day -43

         27. Receipt of blood or blood products, or loss (including blood donations) of 470 mL or
             more of blood during the 3 months prior to the planned date of first dosing with IMP
             or planned during the 3 months after the final visit.

         28. Receipt of systemic (intravenous and/or oral) glucocorticoids or systemic antiviral
             drugs within 6 months prior to the planned date of first dosing with IMP.

         29. Any other finding that, in the opinion of the Investigator, deems the subject
             unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Dennison, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Medicines Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Balpreet Matharu, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>hVIVO Services Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew J Memoli, M.D</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>hVIVO Services Limited</name>
      <address>
        <city>London</city>
        <zip>E1 2AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Stoloff GA, Caparros-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol. 2007 Sep;37(9):2441-9.</citation>
    <PMID>17668898</PMID>
  </reference>
  <reference>
    <citation>Pleguezuelos O, Robinson S, Stoloff GA, Caparrós-Wanderley W. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Vaccine. 2012 Jun 29;30(31):4655-60. doi: 10.1016/j.vaccine.2012.04.089. Epub 2012 May 8.</citation>
    <PMID>22575166</PMID>
  </reference>
  <reference>
    <citation>Pleguezuelos O, Robinson S, Fernández A, Stoloff GA, Mann A, Gilbert A, Balaratnam G, Wilkinson T, Lambkin-Williams R, Oxford J, Caparrós-Wanderley W. A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans. Clin Vaccine Immunol. 2015 Jul;22(7):828-35. doi: 10.1128/CVI.00098-15. Epub 2015 May 20.</citation>
    <PMID>25994549</PMID>
  </reference>
  <reference>
    <citation>Pleguezuelos O, Robinson S, Fernandez A, Stoloff GA, Caparrós-Wanderley W. Meta-Analysis and Potential Role of Preexisting Heterosubtypic Cellular Immunity Based on Variations in Disease Severity Outcomes for Influenza Live Viral Challenges in Humans. Clin Vaccine Immunol. 2015 Aug;22(8):949-56. doi: 10.1128/CVI.00101-15. Epub 2015 Jun 17.</citation>
    <PMID>26084515</PMID>
  </reference>
  <reference>
    <citation>van Doorn E, Pleguezuelos O, Liu H, Fernandez A, Bannister R, Stoloff G, Oftung F, Norley S, Huckriede A, Frijlink HW, Hak E. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial. BMC Infect Dis. 2017 Apr 4;17(1):241. doi: 10.1186/s12879-017-2341-9.</citation>
    <PMID>28376743</PMID>
  </reference>
  <reference>
    <citation>Memoli MJ, Czajkowski L, Reed S, Athota R, Bristol T, Proudfoot K, Fargis S, Stein M, Dunfee RL, Shaw PA, Davey RT, Taubenberger JK. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis. 2015 Mar 1;60(5):693-702. doi: 10.1093/cid/ciu924. Epub 2014 Nov 20.</citation>
    <PMID>25416753</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 31, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <results_first_submitted>March 20, 2019</results_first_submitted>
  <results_first_submitted_qc>April 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2019</results_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>broad</keyword>
  <keyword>universal</keyword>
  <keyword>vaccine</keyword>
  <keyword>influenza</keyword>
  <keyword>peptide</keyword>
  <keyword>T cell</keyword>
  <keyword>H1N1</keyword>
  <keyword>human challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT03180801/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT03180801/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT03180801/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>An excess number of subjects were vaccinated to ensure 123 subjects were able to complete the quarantine period . Any subject that dropped out after vaccination but before inoculation with the challenge virus was replaced with another vaccinated subject.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 Adjuvanted Placebo</title>
          <description>0.5ml adjuvanted placebo (Montanide ISA-51: WFI) on Day -43 and on Day -22 as subcutaneous injection followed by H1N1 influenza challenge on day 0.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 Adjuvanted FLU-v One Dose</title>
          <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 as subcutaneous injection followed by H1N1 influenza challenge on day 0.</description>
        </group>
        <group group_id="P3">
          <title>Group 3 Adjuvanted FLU-v Two Doses</title>
          <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 as subcutaneous injection followed by H1N1 influenza challenge on day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention to Treat</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inoculation Target Reached</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intention to treat (ITT) group was used for all analysis. ITT includes those participants who received both vaccination and challenge with an influenza virus.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1 Adjuvanted Placebo</title>
          <description>adjuvanted placebo on Day -43 and on Day -22 followed</description>
        </group>
        <group group_id="B2">
          <title>Group 2 Adjuvanted FLU-v One Dose</title>
          <description>500mcg adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22</description>
        </group>
        <group group_id="B3">
          <title>Group 3 Adjuvanted FLU-v Two Doses</title>
          <description>500mcg adjuvanted FLU-v vaccine on Day -43 and on Day -22</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="7.5"/>
                    <measurement group_id="B2" value="29.9" spread="8.9"/>
                    <measurement group_id="B3" value="27.4" spread="9.2"/>
                    <measurement group_id="B4" value="28.7" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian/Asian British</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/Black British</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Chinese</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Japanese</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of subjects with challenge strain HAI titers &gt; or = 40 at screening</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Mild to Moderate Influenza Disease (MMID)</title>
        <description>To determine the effect of FLU-v on reducing the incidence of Mild to Moderate Influenza Disease (MMID) defined as detectable viral shedding by Luminex Respiratory Pathogen Panel Test (RPP) in the presence of at least one influenza symptom.</description>
        <time_frame>From 24h post-viral inoculation (Day 1) until the end of the quarantine phase on Day 7</time_frame>
        <population>ITT includes those participants who received both vaccination and were challenged with the H1N1 influenza virus</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Adjuvanted Placebo</title>
            <description>0.5ml adjuvanted placebo on Day -43 and on Day -22</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Adjuvanted FLU-v One Dose</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Adjuvanted FLU-v Two Doses</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mild to Moderate Influenza Disease (MMID)</title>
          <description>To determine the effect of FLU-v on reducing the incidence of Mild to Moderate Influenza Disease (MMID) defined as detectable viral shedding by Luminex Respiratory Pathogen Panel Test (RPP) in the presence of at least one influenza symptom.</description>
          <population>ITT includes those participants who received both vaccination and were challenged with the H1N1 influenza virus</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>positive MMID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative MMID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher exact test is used to test if vaccine group has lower MMID rate than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher exact test is used to test if vaccine group has lower MMID rate than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment Emergent Adverse Events (TEAEs) Per Subject.</title>
        <description>To determine the number of TEAEs that were reported after the first administration of the vaccine until the end of the study (overall) and then separated into pre-inoculation (events reported from the time of first vaccination up to Day 0 prior to time of inoculation) and post-inoculation (Day 0 inoculation time through study completion).</description>
        <time_frame>From the first vaccination on day -43 to the last follow up visit on day 63.</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Adjuvanted Placebo</title>
            <description>0.5ml adjuvanted placebo on Day -43 and on Day -22</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Adjuvanted FLU-v One Dose</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Adjuvanted FLU-v Two Doses</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment Emergent Adverse Events (TEAEs) Per Subject.</title>
          <description>To determine the number of TEAEs that were reported after the first administration of the vaccine until the end of the study (overall) and then separated into pre-inoculation (events reported from the time of first vaccination up to Day 0 prior to time of inoculation) and post-inoculation (Day 0 inoculation time through study completion).</description>
          <population>Safety population</population>
          <units>Number of TEAEs per subject</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="0.26"/>
                    <measurement group_id="O2" value="1.38" spread="0.24"/>
                    <measurement group_id="O3" value="2.35" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-inoculation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.21"/>
                    <measurement group_id="O2" value="0.81" spread="0.13"/>
                    <measurement group_id="O3" value="1.51" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Inoculation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.16"/>
                    <measurement group_id="O2" value="0.58" spread="0.15"/>
                    <measurement group_id="O3" value="0.84" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One sided Fisher's exact test is used to test if the TEAE rates pre-inoculation recorded for the treatment group are higher than for placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>One sided Fisher’s exact test is used to test if TEAE rates of vaccine group is higher than the placebo group.</non_inferiority_desc>
            <p_value>0.647</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test is used to test if TEAE rate of vaccine group recorded pre-inoculation is higher than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One sided Fisher's exact test is used to test if TEAE rate of vaccine group post-inoculation is higher than the placebo group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0240</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One sided Fisher's exact test is used to test if TEAE rate of vaccine group post-inoculation is higher than the placebo group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.186</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Treatment Emergent Adverse Event Classified by Relatedness and Severity.</title>
        <description>Number of subjects with one or more AE are reported by severity (mild, moderate and severe) and relatedness to vaccine or challenge virus inoculation (definitely, probably, possibly, unlikely, not related).</description>
        <time_frame>From the day of the first vaccination up to the end of the study on day +63.</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Adjuvanted Placebo</title>
            <description>0.5ml adjuvanted placebo on Day -43 and on Day -22</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Adjuvanted FLU-v One Dose</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Adjuvanted FLU-v Two Doses</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment Emergent Adverse Event Classified by Relatedness and Severity.</title>
          <description>Number of subjects with one or more AE are reported by severity (mild, moderate and severe) and relatedness to vaccine or challenge virus inoculation (definitely, probably, possibly, unlikely, not related).</description>
          <population>Safety population</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with TEAEs definately related to vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects withTEAEs probably related to vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with TEAEs possibly related to vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with TEAEs unlikely related to vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with TEAEs not related to vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with TEAEs definately related to virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with TEAEs probably related to virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with TEAEs possibly related to virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with TEAEs unlikely related to virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with TEAEs not related to virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with mild TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with moderate TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Severe TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Serious Adverse Events (SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Detectable Viral Shedding and Number of Subjects With Recorded Influenza Symptoms During the Quarantine Period.</title>
        <description>Number of subjects experiencing at least one influenza symptom and at least two influenza symptoms.
Number of subjects with detectable shedding by RPP (Luminex) test from nasal swabs.
Number asymptomatic subjects with detectable virus by RPP (Luminex) test from nasal swabs.</description>
        <time_frame>Quarantine period from day 1 to day 7 post-inoculation.</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Adjuvanted Placebo</title>
            <description>0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Adjuvanted FLU-v One Dose</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Adjuvanted FLU-v Two Doses</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Detectable Viral Shedding and Number of Subjects With Recorded Influenza Symptoms During the Quarantine Period.</title>
          <description>Number of subjects experiencing at least one influenza symptom and at least two influenza symptoms.
Number of subjects with detectable shedding by RPP (Luminex) test from nasal swabs.
Number asymptomatic subjects with detectable virus by RPP (Luminex) test from nasal swabs.</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with at least one symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least two symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with detectable shedding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic subjects with detectable shedding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher exact test is used to test if vaccine group has lower rate of subjects experiencing at least one symptom</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.465</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher exact test is used to test if vaccine group has lower rate of subjects experiencing at least one symptom</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher exact test is used to test if vaccine group has lower rate of subjects experiencing at least two symptoms</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher exact test is used to test if vaccine group has lower rate of subjects experiencing at least two symptoms.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.230</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher exact test is used to test if vaccine group has lower rate of subjects with detectable virus shedding</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher exact test is used to test if vaccine group has lower rate of subjects with detectable virus shedding</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher exact test is used to test if vaccine group has lower rate of subjects asymptomatic with detectable virus shedding</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher exact test is used to test if vaccine group has lower rate of subjects asymptomatic with detectable virus shedding</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Shedding Duration</title>
        <description>Number of days with detectable viral shedding measured using the Luminex Respiratory Pathogen Panel test.</description>
        <time_frame>starting from evening of Day 1 post-inoculation up to Day 7.</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Adjuvanted Placebo</title>
            <description>0.5ml adjuvanted placebo on Day -43 and on Day -22</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Adjuvanted FLU-v One Dose</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Adjuvanted FLU-v Two Doses</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Shedding Duration</title>
          <description>Number of days with detectable viral shedding measured using the Luminex Respiratory Pathogen Panel test.</description>
          <population>ITT</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.36"/>
                    <measurement group_id="O2" value="1.20" spread="0.31"/>
                    <measurement group_id="O3" value="1.90" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has shorter shedding duration than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0501</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has shorter shedding duration than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3139</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Viral Shedding (Area Under the Curve)</title>
        <description>Shedding is quantified by RT-PCR from nasal swabs taken twice daily (am/pm) during the quarantine period. Plotting the log copy number/ml for each time point against time is done to calculate the area under the curve (AUC) using the trapezoidal rule.</description>
        <time_frame>from the evening of Day 1 post-inoculation to the morning of Day 7 (last timepoint before expected quarantine discharge)</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Adjuvanted Placebo</title>
            <description>0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Adjuvanted FLU-v One Dose</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Adjuvanted FLU-v Two Doses</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Total Viral Shedding (Area Under the Curve)</title>
          <description>Shedding is quantified by RT-PCR from nasal swabs taken twice daily (am/pm) during the quarantine period. Plotting the log copy number/ml for each time point against time is done to calculate the area under the curve (AUC) using the trapezoidal rule.</description>
          <population>ITT</population>
          <units>hours*log10copy number/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.67" spread="33.39"/>
                    <measurement group_id="O2" value="98.47" spread="27.39"/>
                    <measurement group_id="O3" value="138.79" spread="31.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has smaller shedding AUC than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.102</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has a smaller shedding AUC than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.481</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Immunogenicity of FLU-v</title>
        <description>To determine the antibody and cellular responses specific to FLU-v.</description>
        <time_frame>At Screening (Day -90 to Day -43), Post-vaccination (Day -2/Day -1/Day 0) and post-influenza challenge (Day 35/Day 63)</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Broadness of Protection</title>
        <description>To determine whether the cellular responses induced by vaccination with FLU-v are able to recognize antigenically different strains of influenza (ie. H1N1, H3N2, H5N1) and in doing so demonstrating the broadness of the response. For this PBMCs from prevaccination, post-vaccination and post-challenge from subjects will be exposed in vitro to different influenza virus strains. Viral recognition by PBMCs will be assessed by measuring secretion of inflammatory cytokines and other inflammatory mediators using techniques such as multiplex ELISA.</description>
        <time_frame>At Screening (Day -90 to Day -43), Post-vaccination (Day -2/Day -1/Day 0) and post-influenza challenge (Day 35/Day 63)</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Viral Load</title>
        <description>Shedding is quantified by RT-PCR from nasal swabs taken twice daily (am/pm) during the quarantine period. Peak viral load is the highest recorded log10copy number/ml.</description>
        <time_frame>from the evening of Day 1 post-inoculation to the morning of Day 7 (last timepoint before expected quarantine discharge)</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Adjuvanted Placebo</title>
            <description>0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Adjuvanted FLU-v One Dose</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Adjuvanted FLU-v Two Doses</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Viral Load</title>
          <description>Shedding is quantified by RT-PCR from nasal swabs taken twice daily (am/pm) during the quarantine period. Peak viral load is the highest recorded log10copy number/ml.</description>
          <population>ITT</population>
          <units>log10copy number/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="0.40"/>
                    <measurement group_id="O2" value="1.54" spread="0.39"/>
                    <measurement group_id="O3" value="2.28" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has lower peak viral shedding than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.128</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has lower peak viral shedding than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.601</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Influenza Symptoms</title>
        <description>Subjects were assessed by the physician whilst under quarantine post-inoculation. The number of days subjects experienced influenza symptoms was recorded.</description>
        <time_frame>from the evening of Day 1 post-inoculation to the morning of Day 7 (last timepoint before expected quarantine discharge)</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Adjuvanted Placebo</title>
            <description>0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Adjuvanted FLU-v One Dose</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Adjuvanted FLU-v Two Doses</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Influenza Symptoms</title>
          <description>Subjects were assessed by the physician whilst under quarantine post-inoculation. The number of days subjects experienced influenza symptoms was recorded.</description>
          <population>ITT</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="0.37"/>
                    <measurement group_id="O2" value="2.67" spread="0.35"/>
                    <measurement group_id="O3" value="2.76" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has shorter duration of symptoms than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.142</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has shorter duration of symptoms than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptoms Experienced Per Subject Per Day.</title>
        <description>Mean of total number of symptoms (upper and lower respiratory and systemic symptoms) experienced calculated as the total sum of symptoms experienced divided by the number of days in which symptoms were collected.</description>
        <time_frame>from the evening of Day 1 post-inoculation to the morning until the day of last symptom noted during the expected quarantine period (up tp Day 7)</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Adjuvanted Placebo</title>
            <description>0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Adjuvanted FLU-v One Dose</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Adjuvanted FLU-v Two Doses</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptoms Experienced Per Subject Per Day.</title>
          <description>Mean of total number of symptoms (upper and lower respiratory and systemic symptoms) experienced calculated as the total sum of symptoms experienced divided by the number of days in which symptoms were collected.</description>
          <population>ITT</population>
          <units>number of symptoms per day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="0.33"/>
                    <measurement group_id="O2" value="2.08" spread="0.32"/>
                    <measurement group_id="O3" value="2.51" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has fewer average number of symptoms than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has fewer average number of symptoms than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.271</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Number of Symptoms Experienced Per Subject in a Single Day.</title>
        <description>The highest level of the total sum of all upper and lower respiratory tract and systemic symptoms recorded on any day starting from the evening of Day 1 post-inoculation until the day of last symptom noted during the expected quarantine period (up to Day 7).</description>
        <time_frame>from the evening of Day 1 post-inoculation until the day of last symptom noted during the expected quarantine period (up to Day 7).</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Adjuvanted Placebo</title>
            <description>0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Adjuvanted FLU-v One Dose</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Adjuvanted FLU-v Two Doses</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Number of Symptoms Experienced Per Subject in a Single Day.</title>
          <description>The highest level of the total sum of all upper and lower respiratory tract and systemic symptoms recorded on any day starting from the evening of Day 1 post-inoculation until the day of last symptom noted during the expected quarantine period (up to Day 7).</description>
          <population>ITT</population>
          <units>number of symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="0.26"/>
                    <measurement group_id="O2" value="1.68" spread="0.22"/>
                    <measurement group_id="O3" value="1.88" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has fewer peak symptoms than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.099</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has fewer peak symptoms than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.178</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Self-reported Influenza Symptoms by FLU-PRO Questionnaire.</title>
        <description>FLU-PRO assesses 32 influenza symptoms. Subjects rate each symptom on a 5-point ordinal scale, with higher scores indicating a more frequent sign or symptom. For 27 of the items, the scale is as follows: 0 (&quot;Not at all&quot;), 1 (&quot;A little bit&quot;), 2 (&quot;Somewhat&quot;), 3 (&quot;Quite a bit&quot;), and 4 (&quot;Very much&quot;). For 5 items, severity is assessed in terms of numerical frequency, i.e., vomiting or diarrhea (0 times, 1 time, 2 times, 3 times, or 4 or more times); with frequency of sneezing, coughing, and coughed up mucus or phlegm evaluated on a scale from 0 (&quot;Never&quot;) to 4 (&quot;Always&quot;).The FLU-PRO total score is computed as a mean score across all 32 items comprising the instrument. Total scores can range from 0 (symptom free) to 4 (very severe symptoms).</description>
        <time_frame>from Day 1 post-inoculation until the day 7.</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Adjuvanted Placebo</title>
            <description>0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Adjuvanted FLU-v One Dose</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Adjuvanted FLU-v Two Doses</title>
            <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Self-reported Influenza Symptoms by FLU-PRO Questionnaire.</title>
          <description>FLU-PRO assesses 32 influenza symptoms. Subjects rate each symptom on a 5-point ordinal scale, with higher scores indicating a more frequent sign or symptom. For 27 of the items, the scale is as follows: 0 (&quot;Not at all&quot;), 1 (&quot;A little bit&quot;), 2 (&quot;Somewhat&quot;), 3 (&quot;Quite a bit&quot;), and 4 (&quot;Very much&quot;). For 5 items, severity is assessed in terms of numerical frequency, i.e., vomiting or diarrhea (0 times, 1 time, 2 times, 3 times, or 4 or more times); with frequency of sneezing, coughing, and coughed up mucus or phlegm evaluated on a scale from 0 (&quot;Never&quot;) to 4 (&quot;Always&quot;).The FLU-PRO total score is computed as a mean score across all 32 items comprising the instrument. Total scores can range from 0 (symptom free) to 4 (very severe symptoms).</description>
          <population>ITT</population>
          <units>FLU-PRO total score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.01"/>
                    <measurement group_id="O2" value="0.03" spread="0.01"/>
                    <measurement group_id="O3" value="0.04" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has lower FLU-PRO scores than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Wilcoxon test is used to test if vaccine group has lower FLU-PRO scores than placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.201</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of first administration of vaccine to the date of inoculation with the challenge virus (TEAEs).</time_frame>
      <desc>Treatment Emergent AEs are all AEs that occur in the period between the first administration of the vaccine and the end of the study independently of their intensity and if they are related or not to the vaccine.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 Adjuvanted Placebo</title>
          <description>0.5ml adjuvanted placebo on Day -43 and on Day -22</description>
        </group>
        <group group_id="E2">
          <title>Group 2 Adjuvanted FLU-v One Dose</title>
          <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22</description>
        </group>
        <group group_id="E3">
          <title>Group 3 Adjuvanted FLU-v Two Doses</title>
          <description>0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="52"/>
                <counts group_id="E3" events="31" subjects_affected="31" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI requires the Sponsor's consent to publish any material that contains Sponsor Property; including Study Data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Olga Pleguezuelos</name_or_title>
      <organization>SEEK</organization>
      <phone>+44 020 7153 6601</phone>
      <email>olga.pleguezuelos@seekacure.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

